Drugs /

ricolinostat

Back to Drugs List
Associated Genetic Biomarkers

Overview

Generic Name(s):
ricolinostat
NCI Definition [1]:
An orally bioavailable, specific inhibitor of histone deacetylase 6 (HDAC6) with potential antineoplastic activity. Ricolinostat selectively targets and binds to HDAC6, thereby disrupting the Hsp90 protein chaperone system through hyperacetylation of Hsp90 and preventing the subsequent aggresomal protein degradation. This leads to an accumulation of unfolded and misfolded ubiquitinated proteins and may eventually induce cancer cell apoptosis, and inhibition of cancer cell growth. HDAC6, a class II HDAC deacetylase located in the cytoplasm, appears to play a key role in the formation and activation of the aggresomes needed for degradation of misfolded proteins. Compared to non-selective HDAC inhibitor, ACY-1215 is able to reduce the toxic effects on normal, healthy cells.

Clinical Trials

View Clinical Trials for ricolinostat

Ricolinostat has been investigated in 1 clinical trial, of which 0 are open and 1 is closed. Of the trial investigating ricolinostat, 1 is phase 1/phase 2 (0 open).

Hodgkin lymphoma, mantle cell lymphoma, and non-hodgkin lymphoma are the most common diseases being investigated in ricolinostat clinical trials [2].

Drug Details

Synonyms [2]:
acy-1215, acy-63, histone deacetylase 6 inhibitoracy-1215, hdac6 inhibitor acy-1215, 2-(diphenylamino)-n-(7-(hydroxyamino)-7-oxoheptyl)pyrimidine-5-carboxamide, ricolinostat, histone deacetylase 6 inhibitoracy-1215, 2-(diphenylamino)-n-(7-(hydroxyamino)-7-oxoheptyl)pyrimidine-5-carboxamide
Drug Categories [2]:
Histone deactylase/HDAC inhibitors
Drug Target(s) [2]:
HDAC6
NCIT ID [1]:
C96431

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.